Immutrin
Next Generation Antibody Therapy for Reversal of Amyloidosis
United Kingdom · $87.0M raised
- Business Model
- B2B
- Website
- immutrin.com
- Total Funding
- $87.0M
- Last Round
- $87.0M Venture RoundMar 2026
- Rounds
- 1
About
Immutrin is a UK-based biotechnology company developing next-generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. Its lead asset targets ATTR cardiomyopathy with a unique mechanism designed to selectively remove established amyloid fibrils. The company was co-founded by Cambridge Innovation Capital alongside Nobel Laureate Sir Gregory Winter FRS and Professor Sir Mark Pepys FRS.
Summary
Immutrin is a Biotech company based in United Kingdom. It has raised $87.0M in total across 1 round, most recently a $87.0M Venture Round round in Mar 2026. Investors include Frazier Life Sciences, F-Prime Capital and Qiming VP.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Mar 2026
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immutrin"><img src="https://indexed.vc/api/badge/company/immutrin" alt="Immutrin on Indexed.vc" width="260" height="76" /></a>